08:17 AM EDT, 07/10/2024 (MT Newswires) -- Context Therapeutics ( CNTX ) said Wednesday it has acquired CT-95, a mesothelin x CD3 T-cell engaging bispecific antibody, from Link Immunotherapeutics.

CT-95 has obtained investigational new drug clearance from the US Food and Drug Administration and is set for phase 1 trial in Q1 next year, Context Therapeutics ( CNTX ) said.

The acquisition will be funded with existing cash, Context Therapeutics ( CNTX ) Chief Executive Officer Martin Lehr said. Financial details were not provided.